

# Joanna Kopecka

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8910307/joanna-kopecka-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

1,992  
citations

29  
h-index

42  
g-index

80  
ext. papers

2,548  
ext. citations

8.6  
avg, IF

4.94  
L-index

#	Paper	IF	Citations
73	Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors.. <i>Pharmaceutics</i> , <b>2022</b> , 14,	6.4	1
72	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 75	12.8	0
71	The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells.. <i>Drug Resistance Updates</i> , <b>2022</b> , 62, 100833	23.2	1
70	Endothelial Cells Promote Osteogenesis by Establishing a Functional and Metabolic Coupling With Human Mesenchymal Stem Cells.. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 813547	4.6	1
69	Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. <i>Pharmacological Research</i> , <b>2021</b> , 175, 105975	10.2	3
68	Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. <i>Bioorganic Chemistry</i> , <b>2021</b> , 119, 105514	5.1	1
67	Hypoxia as a driver of resistance to immunotherapy. <i>Drug Resistance Updates</i> , <b>2021</b> , 100787	23.2	8
66	Endothelial Heme Dynamics Drive Cancer Cell Metabolism by Shaping the Tumor Microenvironment. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
65	Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	1
64	Targeting HIF-1 $\beta$ Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
63	Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 28	12.8	15
62	Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 12132-12151	8.3	6
61	Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models. <i>Cellular Oncology (Dordrecht)</i> , <b>2021</b> , 44, 1307-1323	7.2	6
60	MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
59	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. <i>Cells</i> , <b>2020</b> , 9,	7.9	13
58	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
57	Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death. <i>Cells</i> , <b>2020</b> , 9,	7.9	11

56	Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	47
55	Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R). <i>European Journal of Medicinal Chemistry</i> , <b>2020</b> , 188, 112037	6.8	7
54	Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. <i>Drug Resistance Updates</i> , <b>2020</b> , 49, 100670	23.2	58
53	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , <b>2020</b> , 53, 100718	23.2	52
52	Cholesterol metabolism: At the cross road between cancer cells and immune environment. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2020</b> , 129, 105876	5.6	10
51	Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance. <i>Cells</i> , <b>2020</b> , 9,	7.9	28
50	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. <i>Seminars in Cell and Developmental Biology</i> , <b>2020</b> , 98, 80-89	7.5	8
49	Wnt/IL-1 $\beta$ /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 192-207	7.5	20
48	HIF-1 $\beta$ s over-expressed in leukemic cells from -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2020</b> , 105, 1042-1054	6.6	23
47	ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	62
46	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1458-1471	8.9	29
45	Hyaluronated liposomes containing H <sub>2</sub> S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. <i>Cancer Letters</i> , <b>2019</b> , 456, 29-39	9.9	26
44	Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 4174-4192	8.3	20
43	Nitric Oxide Reinstates Doxorubicin Cytotoxic and Proimmunogenic Effects in Refractory Breast Cancer <b>2019</b> , 325-326		
42	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. <i>Cellular and Molecular Life Sciences</i> , <b>2019</b> , 76, 609-625	10.3	32
41	Loss of C/EBP- $\beta$ LIP drives cisplatin resistance in malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2018</b> , 120, 34-45	5.9	16
40	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 580	5.6	16
39	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. <i>Molecules</i> , <b>2018</b> , 23,	4.8	9

38	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. <i>Oncolimmunology</i> , <b>2018</b> , 7, e1398874	7.2	29
37	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. <i>Journal of Controlled Release</i> , <b>2018</b> , 270, 37-52	11.7	47
36	Increasing intratumor C/EBP- $\beta$ and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 286	12.8	21
35	Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2598-2609	6.1	26
34	PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. <i>Molecular Cancer</i> , <b>2017</b> , 16, 91	42.1	78
33	Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1. <i>Pharmacological Research</i> , <b>2017</b> , 117, 67-74	10.2	31
32	The ATP-binding cassette transporter A1 regulates phosphoantigen release and V $\alpha$ V $\beta$ T cell activation by dendritic cells. <i>Nature Communications</i> , <b>2017</b> , 8, 15663	17.4	39
31	EB Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	28
30	Multi-walled carbon nanotubes directly induce epithelial-mesenchymal transition in human bronchial epithelial cells via the TGF- $\beta$ -mediated Akt/GSK-3 $\beta$ /SNAIL-1 signalling pathway. <i>Particle and Fibre Toxicology</i> , <b>2016</b> , 13, 27	8.4	51
29	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. <i>Oncotarget</i> , <b>2016</b> , 7, 20753-72	3.3	28
28	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and V $\alpha$ V $\beta$ T-Cell Activation By Dendritic Cells. <i>Blood</i> , <b>2016</b> , 128, 3709-3709	2.2	
27	HIF-1 $\alpha$ upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , <b>2016</b> , 128, 305-305	2.2	
26	Effects of Chrysotile Exposure in Human Bronchial Epithelial Cells: Insights into the Pathogenic Mechanisms of Asbestos-Related Diseases. <i>Environmental Health Perspectives</i> , <b>2016</b> , 124, 776-84	8.4	15
25	P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. <i>Oncotarget</i> , <b>2016</b> , 7, 85861-85875	3.3	24
24	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2640-2652	6.1	57
23	Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. <i>Cancer Letters</i> , <b>2015</b> , 360, 219-26	9.9	38
22	The role of C/EBP- $\beta$ in multidrug resistance. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	32
21	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 31461-78	3.3	32

20	Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 6776-93	3.3	77
19	An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126159	3.7	21
18	Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. <i>Oncotarget</i> , <b>2015</b> , 6, 1128-42	3.3	24
17	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , <b>2015</b> , 126, 2925-2925	2.2	
16	The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 1258-69	7.3	34
15	Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. <i>Molecular Pharmaceutics</i> , <b>2014</b> , 11, 3068-79	5.6	27
14	Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling. <i>Cellular and Molecular Life Sciences</i> , <b>2014</b> , 71, 499-516	10.3	38
13	Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2014</b> , 10, 77-87	6	31
12	Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/Ecatenin pathway. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1502-17	1	51
11	Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. <i>Molecular Cancer</i> , <b>2013</b> , 12, 137	42.1	66
10	Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. <i>Molecular Pharmaceutics</i> , <b>2013</b> , 10, 161-74	5.6	52
9	Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. <i>Current Drug Metabolism</i> , <b>2013</b> , 14, 625-40	3.5	60
8	Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e60975	3.7	46
7	Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. <i>Biochemical Journal</i> , <b>2012</b> , 447, 301-11	3.8	24
6	Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. <i>Molecular Pharmaceutics</i> , <b>2011</b> , 8, 683-700	5.6	81
5	Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , <b>2011</b> , 15, 1492-504	5.6	19
4	A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. <i>Journal of Controlled Release</i> , <b>2011</b> , 149, 196-205	11.7	48
3	Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. <i>Biochemical Journal</i> , <b>2011</b> , 439, 141-9	3.8	52

- 2 Pleiotropic effects of cardioactive glycosides. *Current Medicinal Chemistry*, **2011**, 18, 872-85 43 54
- 1 iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. *Molecular Cancer*, **2009**, 8, 108 42.1 61